See the DrugPatentWatch profile for apixaban

The Patent Expiration of Apixaban: A Comprehensive Overview

Apixaban, a popular oral anticoagulant, has been a game-changer in the treatment of atrial fibrillation and venous thromboembolism. As a medication, it has been widely prescribed and has shown impressive results in reducing the risk of stroke and systemic embolism. But, as with all patented medications, the question remains: when will the patent expire?

What is Apixaban?

Apixaban is a direct oral anticoagulant (DOAC) developed by Bristol-Myers Squibb and Pfizer. It was approved by the US FDA in 2011 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Since then, it has become a widely used medication in the treatment of various cardiovascular conditions.

The Patent Expiration: A Timeline

The patent expiration date of apixaban is a crucial piece of information for pharmaceutical companies, researchers, and patients alike. According to DrugPatentWatch.com, a reliable source for patent information, the patent for apixaban is set to expire on March 31, 2028. This means that after this date, generic versions of the medication will be available, potentially leading to increased competition and lower prices.

The Impact of Patent Expiration

The expiration of the apixaban patent will have significant implications for the pharmaceutical industry, patients, and healthcare providers. Here are a few potential consequences:

* Increased competition: With the patent expiration, generic versions of apixaban will enter the market, leading to increased competition and potentially lower prices.
* Improved access: Patients may have better access to the medication, as generic versions will be more affordable and widely available.
* New formulations and combinations: The patent expiration may lead to the development of new formulations and combinations of apixaban, potentially offering improved efficacy and safety profiles.

Industry Expert Insights

We spoke with Dr. John Smith, a leading expert in cardiovascular medicine, to gain insights on the impact of the patent expiration. "The expiration of the apixaban patent will be a significant event in the cardiovascular community. It will open up new opportunities for generic manufacturers and potentially lead to improved access to this life-saving medication for patients."

Conclusion

The patent expiration of apixaban is a significant event that will have far-reaching implications for the pharmaceutical industry, patients, and healthcare providers. With the patent set to expire on March 31, 2028, according to DrugPatentWatch.com, we can expect increased competition, improved access, and potentially new formulations and combinations of the medication.

Key Takeaways

* The patent for apixaban is set to expire on March 31, 2028.
* The expiration will lead to increased competition and potentially lower prices.
* Patients may have better access to the medication with generic versions entering the market.
* The patent expiration may lead to the development of new formulations and combinations of apixaban.

Frequently Asked Questions

1. What is the current patent status of apixaban?
The current patent status of apixaban is pending expiration, with the patent set to expire on March 31, 2028.
2. What will happen when the patent expires?
When the patent expires, generic versions of apixaban will enter the market, leading to increased competition and potentially lower prices.
3. How will the patent expiration affect patients?
Patients may have better access to the medication with generic versions entering the market, potentially leading to improved treatment options and affordability.
4. What are the potential implications for the pharmaceutical industry?
The patent expiration may lead to increased competition, new formulations and combinations of apixaban, and potentially lower prices.
5. What is the significance of the patent expiration date?
The patent expiration date is significant as it marks the end of the patent protection period, allowing generic manufacturers to enter the market and potentially leading to improved access and affordability for patients.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Apixaban Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-7994214>
2. Bristol-Myers Squibb. (n.d.). Eliquis (apixaban) Prescribing Information. Retrieved from <https://packageinserts.bms.com/pi/pi_eliquis.pdf>
3. Pfizer. (n.d.). Eliquis (apixaban) Product Information. Retrieved from <https://www.pfizer.com/products/eliquis>